These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18341876)

  • 21. Empirical Vancomycin Dosing in Pediatric Patients with Congenital Heart Disease and the Impact of Cardiopulmonary Bypass on Trough Concentrations.
    Thomas CA; Picone A; Menon S; Willis BC
    Pharmacotherapy; 2017 Nov; 37(11):1341-1346. PubMed ID: 28833385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.
    Leroux S; Jacqz-Aigrain E; Biran V; Lopez E; Madeleneau D; Wallon C; Zana-Taïeb E; Virlouvet AL; Rioualen S; Zhao W
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2039-42. PubMed ID: 26787690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subgroup identification-based model selection to improve the predictive performance of individualized dosing.
    Soeorg H; Kalamees R; Lutsar I; Metsvaht T
    J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):253-263. PubMed ID: 38400995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule.
    Pawlotsky F; Thomas A; Kergueris MF; Debillon T; Roze JC
    Br J Clin Pharmacol; 1998 Aug; 46(2):163-7. PubMed ID: 9723826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.
    Jacqz-Aigrain E; Leroux S; Thomson AH; Allegaert K; Capparelli EV; Biran V; Simon N; Meibohm B; Lo YL; Marques R; Peris JE; Lutsar I; Saito J; Nakamura H; van den Anker JN; Sharland M; Zhao W
    J Antimicrob Chemother; 2019 Aug; 74(8):2128-2138. PubMed ID: 31049551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.
    Eiland LS; English TM; Eiland EH
    Ann Pharmacother; 2011 May; 45(5):582-9. PubMed ID: 21521865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors impacting unbound vancomycin concentrations in neonates and young infants.
    Smits A; Pauwels S; Oyaert M; Peersman N; Spriet I; Saegeman V; Allegaert K
    Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1503-1510. PubMed ID: 29770901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacokinetics of vancomycin in the neonate: a review.
    Pacifici GM; Allegaert K
    Clinics (Sao Paulo); 2012 Jul; 67(7):831-7. PubMed ID: 22892931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vancomycin cerebrospinal fluid concentrations after intravenous administration in premature infants.
    Reiter PD; Doron MW
    J Perinatol; 1996; 16(5):331-5. PubMed ID: 8915929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achievement of Therapeutic Vancomycin Exposure With Continuous Infusion in Critically Ill Children.
    Genuini M; Oualha M; Bouazza N; Moulin F; Treluyer JM; Lesage F; Renolleau S; Benaboud S
    Pediatr Crit Care Med; 2018 Jun; 19(6):e263-e269. PubMed ID: 29394210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
    Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
    Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacokinetics of vancomycin in neonates of postconceptional age less than or equal to 32 weeks].
    Ginovart Galiana G; Mangues Bafalluy MA; Demestre Guasch X; Farré Riba R; Lopes Santos AP; Altirriba Valls O
    An Esp Pediatr; 1996 Aug; 45(2):167-71. PubMed ID: 8967647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.
    Rodvold KA; Everett JA; Pryka RD; Kraus DM
    Clin Pharmacokinet; 1997 Jul; 33(1):32-51. PubMed ID: 9250422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of vancomycin in neonates.
    Seay RE; Brundage RC; Jensen PD; Schilling CG; Edgren BE
    Clin Pharmacol Ther; 1994 Aug; 56(2):169-75. PubMed ID: 8062493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancomycin: pharmacokinetics and administration regimens in neonates.
    de Hoog M; Mouton JW; van den Anker JN
    Clin Pharmacokinet; 2004; 43(7):417-40. PubMed ID: 15139793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vancomycin trough concentrations in overweight or obese pediatric patients.
    Heble DE; McPherson C; Nelson MP; Hunstad DA
    Pharmacotherapy; 2013 Dec; 33(12):1273-7. PubMed ID: 23798327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children.
    Giachetto GA; Telechea HM; Speranza N; Oyarzun M; Nanni L; Menchaca A
    Pediatr Crit Care Med; 2011 Nov; 12(6):e250-4. PubMed ID: 21057350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
    Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
    J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.
    Anderson BJ; Allegaert K; Van den Anker JN; Cossey V; Holford NH
    Br J Clin Pharmacol; 2007 Jan; 63(1):75-84. PubMed ID: 16869817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric Assessment of Vancomycin Empiric Dosing (PAVED): a Retrospective Review.
    Rainkie D; Ensom MH; Carr R
    Paediatr Drugs; 2015 Jun; 17(3):245-53. PubMed ID: 25813682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.